Rwanda Approves Concession Agreement for Medical Cannabis Project

• The Rwandan Cabinet has approved a concession agreement between the Government of Rwanda and InipasvalleyRw Ltd for the High-Value Therapeutic Crops Project.
• Medical marijuana is the only known high-value therapeutic crop that has been legalized for growth and production in Rwanda.
• The country legalized the cultivation, processing, and export of cannabis for medical and therapeutic purposes in 2021.
• King Kong Organics (KKOG Rwanda) became the first company to secure a five-year licence to cultivate medicinal cannabis in 2024.

Medical marijuana is the only known high-value therapeutic crop that has been legalized for growth and production in Rwanda.

The Rwandan Cabinet has approved a concession agreement between the Government of Rwanda and InipasvalleyRw Ltd for the High-Value Therapeutic Crops Project. The decision was made during a Cabinet meeting chaired by President Paul Kagame on July 24, as reported in resolutions from the meeting. This approval comes at a time when Rwanda is actively promoting investment in high-value therapeutic crops, particularly marijuana. Medical marijuana is the only known high-value therapeutic crop that has been legalized for growth and production in Rwanda. The country legalized the cultivation, processing, and export of cannabis for medical and therapeutic purposes in 2021, while maintaining a ban on recreational use.

The concession agreement between InipasvalleyRw Ltd and the Government of Rwanda has significant implications for investors in Rwanda's high-value therapeutic crops sector. The agreement follows the legalization of medical marijuana in 2021, which allowed for the cultivation, processing, and export of cannabis for medical and therapeutic purposes. However, the approved concession does not specify whether it is specifically for production of medical cannabis. This lack of clarity may raise questions about compliance exposures related to government funding and land title issues. The Rwanda Development Board (RDB) has been involved in facilitating investment in high-value therapeutic crops, but its handling of government commitments and land title issues has raised concerns among investors.

The approval of the concession agreement for InipasvalleyRw Ltd's High-Value Therapeutic Crops Project is a significant development in Rwanda's efforts to promote investment in high-value therapeutic crops. However, the project has faced challenges, including the failure of King Kong Organics (KKOG Rwanda) to secure funding and resolve land title issues. The RDB's handling of government commitments and land title issues has also raised concerns among investors. Lawyers advising clients on investing in Rwanda's high-value therapeutic crops sector should monitor the concession agreement for InipasvalleyRw Ltd and assess potential compliance exposures related to government funding and land title issues.

Lawyers advising clients on investing in Rwanda's high-value therapeutic crops sector should monitor the concession agreement for InipasvalleyRw Ltd and assess potential compliance exposures related to government funding and land title issues.

Source: Original reporting via New Times